United Arab Emirates (UAE) has received a total of 3 million COVID-19 vaccine doses from China National Biotec Group (CNBG), as reported in the Financial Post.
CNBG, a subsidiary of state-backed Sinopharm, has moved two COVID-19 vaccine candidates, developed by its units in Beijing and Wuhan, into late-stage clinical trials.
The Beijing unit's candidate obtained authorisation last week for general public use in China.
"According to preliminary feedback from UAE, emergency use shows that Sinopharm CNBG's COVID-19 vaccine is safe in large-scale use and has significantly reduced the disease in vaccinated people," CNBG said in an article published on WeChat, without specifying which candidate it referred to.
To read more NewsPoints articles, click here.